Top 20 of Choroidal Neovascularization

Article title # Publications/# Citations

Ranibizumab for neovascular age-related macular degeneration.

2006: MARINA Study Group; DSBoyer; DMBrown; CYChung; JSHeier; PKKaiser; RYKim; PJRosenfeld;

469

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

2006: ANCHOR Study Group; DMBrown; JSHeier; PKKaiser; RYKim; MMichels; SSchneider; GSoubrane; JPSy;

289

Pegaptanib for neovascular age-related macular degeneration.

2004: VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group; APAdamis; ETCunningham; MFeinsod; ESGragoudas; DRGuyer;

255

Current concepts in the pathogenesis of age-related macular degeneration.

2004: MAZarbin;

169

Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.

1999:

149

Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.

2006: RLAvery; AACastellarin; MJGiust; MANasir; DJPieramici; MDRabena;

134

Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2.

2001: Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group; NMBressler;

118

CX3CR1-dependent subretinal microglia cell accumulation is associated with cardinal features of age-related macular degeneration.

2007: FBehar-Cohen; DChauvaud; SChemtob; SYCohen; CCombadière; PDebré; PDeterre; TFerroukhi; ... CFeumi; MHoussier; JCJeanny; LJonet; NKeller; SLavalette; APezard; EPicard; WRaoul; MRodero; FSennlaub; MSirinyan;

107

Enhanced depth imaging spectral-domain optical coherence tomography.

2008: HKoizumi; MCPozonni; MCPozzoni; RFSpaide;

107

An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.

2007: JLDavis; SRDubovy; MEsquiabro; WJFeuer; HWFlynn; AEFung; GALalwani; SMichels; CAPuliafito; PJRosenfeld;

93

Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration.

2005 Jul-Aug: AAMoshfeghi; CAPuliafito; PJRosenfeld;

92

Drusen complement components C3a and C5a promote choroidal neovascularization.

2006: BKAmbati; JAmbati; JZBaffi; SRBarnum; YChen; JDLambris; MNozaki; BJRaisler; ... ESakurai; JVSarma; KZhang;

91

Risk factors for the incidence of Advanced Age-Related Macular Degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report no. 19.

2005: Age-Related Eye Disease Study Research Group; TEClemons; FLFerris; RKlein; RCMilton; JMSeddon;

91

Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.

2009: ANCHOR Study Group; DMBrown; JSHeier; TIanchulev; PKKaiser; MMichels; JPSy;

83

Macrophage depletion inhibits experimental choroidal neovascularization.

2003: BKAmbati; JAmbati; AAnand; ESakurai; Nvan Rooijen;

81

Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2.

2001: Verteporfin in Photodynamic Therapy Study Group;

78

Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization.

2002: CCohen; SDithmar; SGElner; VMElner; HEGrossniklaus; DHLawson; JXLing; PSternberg; TMWallace;

76

Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.

2006: LDamico; NFerrara; RKim; HLowman; NShams;

75

Macrophage depletion diminishes lesion size and severity in experimental choroidal neovascularization.

2003: SWCousins; KGCsaky; DGEspinosa-Heidmann; EPHernandez; DMonroy; IJSuñer;

72

Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1.

2008: PAbraham; DMBrown; TIanchulev; CDRegillo; SSchneider; NShams; HYue;

69